Vulvovaginal candidiasis
Pro Research Analysisby 
Searched over 200M research papers for "vulvovaginal candidiasis"
Epidemiology and Prevalence of Vulvovaginal Candidiasis
Vulvovaginal candidiasis (VVC) is a very common infection, affecting up to 75% of women of reproductive age at least once in their lifetime, with about 5–10% experiencing recurrent episodes (RVVC) 24910. The condition is most prevalent among healthy, immunocompetent women, especially during their childbearing years 134.
Causes and Risk Factors for Vulvovaginal Candidiasis
The main cause of VVC is the overgrowth of Candida species, particularly Candida albicans, though non-albicans species like Candida glabrata are increasingly recognized 1346. Several factors can increase the risk of developing VVC, including pregnancy, diabetes, immunosuppression, antibiotic use, hormone replacement therapy, and genetic predispositions 24610. Behavioral factors such as use of oral contraceptives, intrauterine devices, spermicides, condoms, and certain hygiene or sexual practices also contribute to risk 410.
Pathogenesis and Host Response in Vulvovaginal Candidiasis
VVC is characterized by an imbalance between Candida colonization and the host environment, often triggered by physiological or external changes 14. The disease is marked by pathologic inflammation, with symptoms largely driven by immune responses, particularly neutrophil-associated dysfunction 19. Unlike other forms of candidiasis, VVC typically affects otherwise healthy women 13.
Clinical Presentation and Diagnosis of Vulvovaginal Candidiasis
Typical symptoms include vulval itching, soreness, non-offensive vaginal discharge (often curd-like but sometimes thin or absent), and superficial pain during intercourse . Diagnosis relies on clinical assessment and, when necessary, laboratory tests to confirm the presence and type of Candida species 3510. Fast and reliable diagnosis is important for effective treatment .
Management and Treatment Approaches
Most uncomplicated cases of VVC can be managed with a variety of effective oral or topical antifungal treatments 238. For recurrent cases, management includes identifying and eliminating predisposing factors, confirming the Candida species, and using induction therapy followed by maintenance suppressive therapy, often with fluconazole 6710. However, fluconazole resistance and the need for species-specific treatment are growing concerns 67. Guidelines recommend therapy tailored to the specific Candida species and patient needs 357.
Challenges and Future Directions
Despite its high prevalence and impact on quality of life, VVC remains under-recognized in public health and research 15. Recurrent VVC is particularly challenging to cure, especially with rising antifungal resistance 67. There is ongoing research into the roles of the vaginal microbiome, host immune responses, and the development of vaccines or novel therapies 19.
Conclusion
Vulvovaginal candidiasis is a widespread and impactful condition, primarily caused by Candida albicans but increasingly by non-albicans species. It is influenced by a range of host, behavioral, and environmental factors. While most cases are treatable, recurrent infections pose significant challenges, highlighting the need for continued research into prevention, diagnosis, and new treatment strategies 1346+3 MORE.
Sources and full results
Most relevant research papers on this topic